Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP3 | P08254 | 2/20 | 0.30 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP7 | P09237 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16975025 | 1.00 | TP53 (0.35) | TP53SMN1; SMN2ALDH1A1LMNAGAA | |
| SCHEMBL31472581 | 0.82 | MME (0.37) | — | |
| SCHEMBL31378136 | 0.82 | — | — | |
| SCHEMBL1162263 | 0.81 | ALDH1A1 (0.47) | ALDH1A1FPR2 | |
| SCHEMBL1162265 | 0.81 | ALDH1A1 (0.47) | ALDH1A1FPR2 | |
| SCHEMBL866892 | 0.78 | — | — | |
| SCHEMBL866893 | 0.78 | — | — | |
| SCHEMBL12487823 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL25266273 | 0.77 | TP53 (0.36) | TP53 | |
| Hydrochloric Acid SCHEMBL7721977 | 0.77 | TP53 (0.36) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652459-A2 | CALCIUM INDEPENDENT PHOSPHATIDYLSERINE BINDING COMPOUNDS FOR DETECTING PHOSPHATIDYLSERINE POSITIVE CELLS | Biolegend, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| US-20240262865-A1 | Calcium independent phosphatidylserine binding compounds for detecting phosphatidylserine positive cells | BioLegend, Inc. | 2024-08-08 | — | — | US | claimed |
| WO-2024155787-A2 | CALCIUM INDEPENDENT PHOSPHATIDYLSERINE BINDING COMPOUNDS FOR DETECTING PHOSPHATIDYLSERINE POSITIVE CELLS | ZHANG HONG (US) | 2024-07-25 | — | — | WO | claimed |
| EP-4652459-A2 | CALCIUM INDEPENDENT PHOSPHATIDYLSERINE BINDING COMPOUNDS FOR DETECTING PHOSPHATIDYLSERINE POSITIVE CELLS | Biolegend, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025125302-A1 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-06-19 | — | — | WO | disclosed |
| CN-119792560-A | Albumin-paclitaxel twin drug nanoparticle based on dipeptide linker and application thereof | 浙江工业大学 | 2025-04-11 | — | — | CN | disclosed |
| US-20240262865-A1 | Calcium independent phosphatidylserine binding compounds for detecting phosphatidylserine positive cells | BioLegend, Inc. | 2024-08-08 | — | — | US | disclosed |
| WO-2024155787-A2 | CALCIUM INDEPENDENT PHOSPHATIDYLSERINE BINDING COMPOUNDS FOR DETECTING PHOSPHATIDYLSERINE POSITIVE CELLS | ZHANG HONG (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20230381324-A1 | SMALL MOLECULE DRUG CONJUGATES | EIDGENOESSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2023-11-30 | — | — | US | disclosed |
| CN-115594732-A | Linker-drug conjugate, preparation method and application thereof | 泰州复旦张江药业有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| EP-3928796-A1 | SMALL MOLECULE DRUG CONJUGATES | Eidgenöessische Technische Hochschule Zurich (CH) | 2021-12-29 | — | — | EP | disclosed |
| EP-3102241-B1 | SMALL MOLECULE DRUG CONJUGATES | EIDGENOESSICHE TECHNISCHE HOCHSCHULE ZUERICH (CH) | 2019-04-17 | — | — | EP | disclosed |
| EP-3424537-A1 | SMALL MOLECULE DRUG CONJUGATES | Eidgenössiche Technische Hochschule Zürich (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-20180280523-A1 | Small Molecule Drug Conjugates | ETH-ZURICH (CH) | 2018-10-04 | — | — | US | disclosed |
| US-10016511-B2 | Small molecule drug conjugates | ETH ZURICH (CH) | 2018-07-10 | — | — | US | disclosed |
| US-9884122-B2 | Small molecule drug conjugates | ETH ZURICH (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20170224831-A1 | Small Molecule Drug Conjugates | ETH ZURICH (CH) | 2017-08-10 | — | — | US | disclosed |
| US-20170035892-A1 | Small Molecule Drug Conjugates | ETH ZURICH (CH) | 2017-02-09 | — | — | US | disclosed |
| EP-3102241-A1 | SMALL MOLECULE DRUG CONJUGATES | Eidgenössiche Technische Hochschule Zürich (CH) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015114171-A1 | SMALL MOLECULE DRUG CONJUGATES | EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381324-A1 | SMALL MOLECULE DRUG CONJUGATES | CA9, CA12, CA2 | TP53 653/4885SMN1; SMN2 3739/4885ALDH1A1 1407/4885 |
| US-20180280523-A1 | Small Molecule Drug Conjugates | CA9, CA12, CA2 | TP53 653/4885SMN1; SMN2 3739/4885ALDH1A1 1407/4885 |
| US-20170035892-A1 | Small Molecule Drug Conjugates | CA9, CA11, CA4 | TP53 1042/4885SMN1; SMN2 3825/4885ALDH1A1 594/4885 |
| US-10016511-B2 | Small molecule drug conjugates | CA9, CA12, CA2 | TP53 653/4885SMN1; SMN2 3739/4885ALDH1A1 1407/4885 |
| US-20170224831-A1 | Small Molecule Drug Conjugates | CA9, CA12, CA2 | TP53 653/4885SMN1; SMN2 3739/4885ALDH1A1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.